Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2007-10-17

Last Posted Date: 2019-01-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 86

Registration Number: NCT00545714

Locations: 🇪🇸
Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia, Zaragoza, Spain
🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇪🇸
Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain

and more 30 locations

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Precancerous/Nonmalignant Condition
Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: cyclosporine
Drug: cyclophosphamide
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: sirolimus
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-10-16

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 260

Registration Number: NCT00544115

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

Phase 1

Active, not recruiting

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-10-16

Last Posted Date: 2024-02-16

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 75

Registration Number: NCT00544466

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2007-10-12

Last Posted Date: 2016-05-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00543114

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: ARA-C
Drug: BCNU
Drug: Campath-1H
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine
Drug: Melphalan
Drug: Rituximab
Other: Allogeneic Stem Cell Transplantation
Radiation: Total body radiation (TBI)
Drug: Methotrexate
Drug: Tacrolimus
Procedure: Adback NK or T Cell

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00536978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: lenalidomide
Drug: Rituximab
Drug: Fludarabine

First Posted Date: 2007-09-27

Last Posted Date: 2017-01-16

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 64

Registration Number: NCT00536341

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
National Capital Clinical Research Consortium, Bethesda, Maryland, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 3 locations

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: natural killer cell therapy
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2007-09-10

Last Posted Date: 2016-02-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00526292

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Alemtuzumab
Drug: Rituximab

First Posted Date: 2007-09-06

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00525603

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Non-Myeloablative Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Procedure: Allogeneic Stem Cell Infusion
Drug: Alemtuzumab

First Posted Date: 2007-09-06

Last Posted Date: 2011-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00525876

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2

Terminated

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Melphalan
Drug: Thymoglobulin

First Posted Date: 2007-09-03

Last Posted Date: 2013-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00523809

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy